Tech Company Financing Transactions
Atara Biotherapeutics Funding Round
On 1/10/2014, Atara Biotherapeutics raised $13.5 million in Series B investment from Alexandria Venture Investments, Amgen Ventures and Celgene.
Transaction Overview
Company Name
Announced On
1/10/2014
Transaction Type
Venture Equity
Amount
$13,500,000
Round
Series B
Investors
Proceeds Purpose
Proceeds will be used to accelerate the clinical development of Atara's two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months. PINTA 745 is a myostatin inhibiting peptibody in Phase 2 development as a potential treatment for protein energy wasting (PEW), a form of inflammation, malnutrition and muscle wasting in patients with end-stage renal disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
611 Gateway Blvd. 900
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pascal Touchon
Chief Financial Officer
Utpal Koppikar
Chief Medical Officer
AJ Joshi
Chief Scientific Officer
Christopher Haqq
Chief Technical Officer
Joe Newell
VP - Human Resources
Steve Bertram
Browse more venture capital transactions:
Prev: 1/10/2014: EarlyShares venture capital transaction
Next: 1/11/2014: Path venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs